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BREAST IMAGING REPORTING AND DATA SYSTEM – BI-RADS®:
POSITIVE PREDICTIVE VALUE OF CATEGORIES 3, 4 AND 5.
A SYSTEMATIC LITERATURE REVIEW*
Fabíola Procaci Kestelman1, Gustavo Antônio de Souza2, Luiz Claudio Thuler3, Gabriela Martins4,
Vivianne Aguilera Rolim de Freitas4, Ellyete de Oliveira Canella5
OBJECTIVE: To review the literature about the positive predictive value of Breast Imaging Reporting and
Data System (BI-RADS®) categories 3, 4 and 5. MATERIALS AND METHODS: A research was performed in
the online Medline database, entering the terms “predictive value” and “BI-RADS”. Eleven studies were in-
cluded in this review. RESULTS: The positive predictive values ranged respectively between 0% and 8%,
4% and 62%, and 54% and 100% for BI-RADS® categories 3, 4 and 5. Three studies have also evaluated
morphological criteria with higher positive predictive value in mammography, mass with spiculated margins
being the finding with highest positive predictive value for malignancy. CONCLUSION: A high variability was
found in the reviewed literature among positive predictive values of BI-RADS® categories 3, 4 and 5, al-
though methodological differences have been identified, limiting the comparative analysis.
Keywords: Mammography; BI-RADS®; Breast cancer.
Breast Imaging Reporting and Data System – BI-RADS®: valor preditivo positivo das categorias 3, 4 e 5.
Revisão sistemática da literatura.
OBJETIVO: Avaliar artigos, na literatura, que verificam o valor preditivo positivo das categorias 3, 4 e 5 do
Breast Imaging Reporting and Data System (BI-RADS®). MATERIAIS E MÉTODOS: Foi realizada pesquisa na
base de dados Medline utilizando os termos “predictive value” e “BI-RADS”. Foram incluídos 11 artigos nesta
revisão. RESULTADOS: O valor preditivo positivo das categorias 3, 4 e 5 variou entre 0% e 8%, 4% e 62%,
54% e 100%, respectivamente. Três artigos avaliaram, concomitantemente, os critérios morfológicos das
lesões que apresentaram maior valor preditivo positivo na mamografia, sendo nódulo espiculado o critério
com maior valor preditivo positivo. CONCLUSÃO: Houve grande variabilidade do valor preditivo positivo das
categorias 3, 4 e 5 do BI-RADS® em todos os estudos, porém foram identificadas diferenças metodológicas
que limitaram a comparação desses estudos.
Unitermos: Mamografia; BI-RADS® ; Câncer de mama.
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cident type of cancer, according to Instituto
Nacional de Câncer statistics(1). The de-
crease in mortality rate depends on an early
detection, an adequate therapeutic plan-
ning, and the adoption of the annual mam-
mography as screening method(2).
Mammography presents high sensitiv-
ity in the detection of clinically occult
breast cancer. A review of clinical trials
evaluating the performance of the method
has demonstrated that the sensitivity ranged
between 71% and 98% for the annual
screening mammography(3). However,
many lesions deemed suspicious with in-
dication for histopathological evaluation
correspond to benign alterations. In the
United States, the positive predictive value
(PPV) of biopsies performed because of
mammographic findings, that is to say, the
total of diagnosed malignant lesions in re-
lation to the total number of biopsies per-
formed, ranges between 15% and 40%(4–6).
The cost and morbidity of the procedures
for the diagnosis of these lesions are taken
into consideration to confirm the adoption
of mammography as a screening method(7).
One of the difficulties in the evaluation
of mammograms is that the greatest part of
the diagnosed lesions does not present
pathognomonic characteristics. Knutzen &
Gisvold(8) have studied the probability of
malignancy in several categories of non-
palpable lesions detected by mammogra-
phy, and observed that, if the morphologi-
cal criteria of these lesions were taken into
consideration, the rate of malignant lesions
among women submitted to biopsy could
reach 40%.
Aiming at reducing the discordance in
the interpretation of mammographic find-
ings and standardizing the terms for char-
acterization and reporting, the American
College of Radiology published, in 1993,
the Breast Imaging Reporting and Data
INTRODUCTION
Breast cancer is the main cause of death
due to neoplasm amongst women in Bra-
zil, corresponding to the second most in-
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System (BI-RADS®)(9). New editions were
released in 1995, 1998 and 2003(10–12).
According to the latest (fourth) edition of
BI-RADS®(12), the studies are classified
with basis on the lesions’ suspicion level
into: category 1 – without positive find-
ings; category 2 – benign findings; cat-
egory 3 – probably benign findings; cat-
egory 4 – suspicious findings; category 5
– findings highly suggestive of malignancy.
Lesions requiring additional evaluation, for
example with ultrasound, are classified into
category 0, and those with previously con-
firmed histopathological diagnosis of ma-
lignancy, into category 6.
The BI-RADS® latest edition included
suggestions for evaluation of breast lesions
with ultrasound and magnetic resonance
imaging. Notwithstanding its great utility
already observed in relation to the BI-
RADS® for mammography, the use of this
lexicon is still recent, generating some criti-
cism and considerations(13,14).
Some studies evaluate the capacity to
predict malignancy of categories 3, 4 and
5 where lesions presenting some level of
suspicion would be included. A way to
evaluate the performance of each BI-
RADS® category is to analyse the results
of lesions submitted to biopsy, and calcu-
late the PPV considering the histopatho-
logical result as the gold-standard.
This literature review is aimed at evalu-
ating the PPV of BI-RADS® categories 3,
4 and 5. Additionally, morphological crite-
ria utilized for stratification of lesions were
analyzed.
MATERIALS AND METHODS
The literature review was performed by
means of a search in the online Medline
database, by entering the terms “predictive
value” and “BI-RADS®”. The publications
included in the present review have met the
following criteria: original articles evalu-
ating the PPV of BI-RADS® categories 3,
4 and 5; PPV analysis based on histopatho-
logical results; studies published from
1998; papers written in Portuguese, En-
glish or French. Studies evaluating only
one or two categories, or whose online ab-
stract was not available were excluded.
The selected original articles were inte-
grally evaluated in order to confirm their
compliance with the above mentioned cri-
teria. Nine of the 33 studies found in the
search have met these criteria. By means of
the bibliographic references in these nine
studies, we have found other two compli-
ant studies, totalling 11 articles.
The data extracted from the articles
were registered on an Excel® (Microsoft)
worksheet. The following items were in-
cluded: study period; number of lesions
evaluated; patients’ages; type of lesion
(palpable/non-palpable); biopsy method;
clinical, radiological or surgical manage-
ment of the lesions submitted to percuta-
neous biopsy; PPV of BI-RADS® catego-
ries 3, 4 and 5; morphological criteria
analysis.
The categories’ PPVs have been ex-
tracted from the articles or calculated
through the data available, considering the
number of lesions in one of the categories
with malignant diagnosis divided by the
total number of lesions classified into this
category, and finally multiplied by 100. In
this case, the histological results classified
as malignant were ductal carcinoma in situ
or any other primary, invasive breast tumor,
according to BI-RADS® recommenda-
tions(12).
Only one study has evaluated both le-
sions submitted to some biopsy method and
lesions under radiological follow-up. In
this case, the PPV was calculated consid-
ering only the lesions initially submitted to
biopsy(15), with the histopathological crite-
ria as the gold-standard.
RESULTS
The 11 articles reviewed reported the
data required for determination of catego-
ries 3, 4 and 5 PPV. Data from these stud-
ies are summarized in Table 1.
In three articles, information was ob-
tained exclusively from patients submitted
to surgical biopsy(16–18). Five studies re-
ported the assessment of patients submit-
ted to percutaneous biopsy(19–23), and two
studies evaluated results of patients submit-
ted to percutaneous biopsy and patients
submitted to surgical biopsy in conjunc-
tion(15,24). Liberman et al. have studied
separately patients submitted to percutane-
ous biopsy and patients submitted to sur-
gical biopsies(25). Ta
b
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As regards the studies based on percu-
taneous biopsies, four of them refer to the
follow-up of patients both by radiological
follow-up of lesions with benign histologi-
cal diagnosis, and by analysis of histologi-
cal results from later surgical biopsies, for
example, in cases with initial histological
diagnosis of atypical ductal hyperpla-
sia(20-22,25). In the other studies, these data
are incomplete. Bérubé et al.(19) have re-
ported a new biopsy in cases where there
was disagreement between the histological
report and the radiological aspect of the
lesion. Two studies have correlated histo-
logical results of atypical hyperplasia with
those of surgical biopsy(23,24). Zonderland
et al.(15) describe the clinical management
of lesions by means of data from de insti-
tution itself and from a national register of
histopathological studies results.
As regards selection of patients consid-
ering the physical examination of their
breasts, the studies have not followed a
homogeneous criterion. Eight of them re-
port physical examination, with four evalu-
ating only non-palpable lesions(16,17,22,25)
and the others have report assessment of
both palpable and non-palpable le-
sions(15,18,21,24). Three articles have not
clearly described the type of lesions stud-
ied(19,20,23), however, they have assessed
patients submitted to ultrasound- or stereo-
tactic-guided percutaneous biopsy, which
may indicate that these lesion are clinically
occult. In the study where Liberman et
al.(25) have evaluated patients submitted to
percutaneous biopsy, these data are not
sufficiently defined, but the lesions have
also been submitted to ultrasound- or ster-
eotactic-guided biopsy.
PPV of categories 3, 4 and 5
In the 11 studies, the PPV ranged be-
tween 0% and 8% for category 3 (median,
2%), 4% and 63% for category 4 (median,
21%), and between 54% and 100% for
category 5 (median, 89%)(Figure 1). In the
four studies where the method for obtain-
ing the histopathological result was exclu-
sively surgical biopsy, the PPV found for
categories 3, 4 and 5 ranged, respectively,
between 0% and 5%, 26% and 34%, and
between 81% and 97%(16–18,25). In the six
studies evaluating lesions submitted only
to percutaneous biopsy, the PPV for cat-
egories 3, 4 and 5 ranged, respectively, be-
tween 0% and 4%, 4% and 20%, and be-
tween 54% and 92%(19–23,25).
The four studies evaluating only non-
palpable lesions(16,17,22,25) presented a PPV
variation, for category 3, between 0% and
2%, for category 4, between 20% and 34%,
and, for category 5, between 77% and 97%.
The four articles reporting results from
palpable and non-palpable lesions(15,18,21,24)
demonstrated a PPV variation, for category
3, between 3% and 8%, for category 4,
between 10% and 63%, and for category 5,
between 84% and 100%.
Morphological criteria with higher PPV
Three articles have mentioned the mor-
phological characteristics of the lesions
with major association with malignancy.
Liberman et al.(25) and Bérubé et al.(19) have
evaluated morphological characteristics of
lesions as proposed by the second edition
of BI-RADS®(12), including, for analysis of
masses, the evaluation of margins and
shape, and for calcifications, the morphol-
ogy and distribution (Table 2). Mendez et
al.(23) have classified the lesions into
microcalcifications, asymmetrical density,
circumscribed mass, spiculated or with
microcalcifications, and asymmetrical den-
sity with microcalcifications. In the three
studies, spiculated mass has been the lesion
with highest PPV(19,23,25). As regards
masses, Liberman et al.(25) have observed
that the criteria with higher PPV were
spiculated margins and irregular shape;
and, as regards microcalcifications, were
linear morphology and segmental or linear
distribution. Bérubé et al.(19) have reported
that the morphological criteria with higher
PPV were dense masses, massed with spi-
culated margins, and linear microcalcifi-
cations.
DISCUSSION
The studies analyzed with the purpose
of evaluating the PPV for BI-RADS® cat-
egories 3, 4 and 5 demonstrated a signifi-
cant difference in the cancer detection
among these categories. However, the
methodology utilized in those studies was
Table 2 Radiological findings with highest PPV, according to BI-RADS®.
Study
Liberman et al.(25), 1998
Bérubé et al.(19), 1998
Morphological criteria
Mass with spiculated margin
Irregularly shaped mass
Microcalcifications with linear morphology
Microcacifications with segmental distribution
Microcalcifications with linear distribution
Dense mass
Mass with spiculated margin
Microcalcifications with linear morphology
PPV
81%
73%
81%
74%
68%
90%
91%
80%
Figure 1. Positive predictive values reported in studies for BI-RADS® categories.
BI-RADS
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quite heterogeneous, limiting the compari-
son between results. Some studies pre-
sented limited information regarding pa-
tients selection. Some of them do not men-
tion if the lesions were palpable or non-
palpable. In the articles where there is no
reference to the type of the studied lesions,
the histopathological result was obtained
by means of ultrasound- or stereotactic-
guided percutaneous biopsy, suggesting
that the lesions were clinically occult. The
variation of the carcinomas prevalence in
these studies and, consequently, of PPV for
categories, may be related with the differ-
ences in the selection of patients for surgi-
cal or percutaneous biopsy.
Another factor that may influence the
carcinomas prevalence is the radiological
follow-up of lesions with benign histo-
pathological diagnosis. In studies with fol-
low-up of patients after core needle (14
gauge) biopsy, the frequency of non-diag-
nosed carcinomas ranged between 0.3%
and 8.2%, and, with the radiological fol-
low-up, 70% of these carcinomas were
immediate false negative, and 30%, de-
layed false negative(26,27).
Additionally, as regards the number of
carcinomas diagnosed by percutaneous
biopsy, another variable should be consid-
ered: the management of underestimated
lesions. For example, a lesion diagnosed as
atypical ductal hyperplasia, after percuta-
neous biopsy, may correspond to a ductal
carcinoma in situ or an invasive ductal car-
cinoma. As regards lesions diagnosed as
atypical ductal hyperplasia, when submit-
ted to core needle (14 gauge) biopsy, 20%
to 56% correspond to carcinomas in surgi-
cal biopsies, while 0% to 38% of lesions
submitted to directional vacuum-assisted
biopsy (mammotomy) with 14- or 11-
gauge needle are underestimated as atypi-
cal ductal hyperplasia. These data demon-
strate that, when the volume of biopsy tis-
sue acquired is higher, the underestimation
rate is lower, although not non-existent(28).
Considering these data, the studies ana-
lyzed also demonstrate heterogeneous char-
acteristics. Six(15,20,22–25) of the eight ar-
ticles(15,19–25) where the histopathological
results have been obtained from lesions
submitted to percutaneous biopsy report
the radiological follow-up of benign le-
sions and surgical biopsy of determined
benign lesions, for example, atypical duc-
tal hyperplasia. Considering that these two
variables affect the number of malignant
diagnoses, studies presenting homogeneity
between these aspects may show differ-
ences in their results.
Another important factor for the analy-
sis of the categories´ PPV is related to the
use of BI-RADS®, which may be limited by
deficiencies in the classification or training
of radiologists(29,30). Berg et al.(31) have
evaluated inter- and intraobserver variabil-
ity in the utilization of the BI-RADS® ter-
minology. Five mammography-experi-
enced radiologists have assessed 103 rou-
tine mammograms. The rate of agreement
among the radiologists (kappa statistical
method) ranged between 0.16 and 0.77 for
the several mammographic findings, show-
ing moderate variability, and 0.37 for BI-
RADS® categories, corresponding to poor
agreement. Orel et al.(16), analyzing the
mammographic findings in different insti-
tutions, have observed that some patients
referred for biopsy presented benign le-
sions classified as BI-RADS® category 2
and, therefore, biopsy would not be indi-
cated. This discrepancy was associated
with the interobserver variation, both for
describing the lesions and for recommend-
ing biopsy, and also was associated with
variations in the experience of the radiolo-
gists involved in the mammograms analy-
sis. Bérubé et al.(19) have associated the low
PPV obtained for category 4 with the fact
of the BI-RADS® nomenclature being de-
scriptive and poorly specific.
Contrarily to Bérubé et al.(19), Zonder-
land et al.(15) have found higher PPVs for
all the categories, in comparison with re-
sults found in American studies. This find-
ing has been attributed to the fact that, in
the American studies, there is a tendency
to get a higher number of positive diag-
noses based on biopsy in order to reduce
the number of false-negative results from
mammography. This affects the selection of
patients for histopathological investigation.
The same finding is reported by a study
comparing routine mammograms per-
formed in the United States and in the
United Kingdom(32).
As regards PPVs of categories, the BI-
RADS® suggests values below 2% for cat-
egory 3 and above 95% for category 5,
while five studies have found values above
the one suggested for category 3(15,18,21,
23,24)
, and in nine articles the values were
lower than expected for category 5(17–25).
Finally, the present review demonstrates
that in all of the studies there was a high
variability in PPVs of BI-RADS® catego-
ries 3, 4 and 5. The comparison among re-
sults from the 11 studies is limited by the
heterogeneity in the criteria for patients
selection, biopsy methods, and, in the case
of the studies with results from percutane-
ous biopsy, by the heterogeneity in the ra-
diological follow-up of both benign and
underestimated lesions. However, there is
a scale for malignancy prediction allowing
the definition, with a relative assurance, of
patients with higher risk of breast cancer.
Additionally, the studies demonstrate that
the presence of spicutated mass presents a
high association with malignancy.
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